the latter being the only subject to date of a published
synthetic approach.19 However, a survey of the literature
revealed limited examples of the enolate chemistry of
R-(N-indolyl)carboxyl substrates20 and only a sole example
leading to a quaternary center,20c raising concerns about
the viability of these species in the arylation process. In
the event, under our standard conditions, compound 5p
underwent efficient arylation to deliver the desired ary-
lation product 6p in 65% yield (Scheme 1). This com-
Table 2. Substrate Scope of Enolate Arylation Approach to
Quaternary Aminooxindoles
Scheme 1. Arylation Reactions of Indole-Containing Substrates
pound was accompanied by a small amount (3%) of what
appeared to be the indolo-fused benzodiazepinone 7a, the
product of a competing direct intramolecular C2-arylation
of the indole.21 The identity of the compound and its likely
mechanism of formation were established by repeating the
reaction under identical conditions, but utilizing only
sufficient base to liberate the free phosphine ligand. In
the absence of any base to promote enolate formation,
compound 7 was the sole product of the reaction, isolated
in a modest 26% yield. Interestingly, compounds with this
heterocyclic skeleton have been shown to have interesting
activity against hepatitis C virus,22 and further optimiza-
tion of this reaction may provide a useful approach to
this system. In this regard, when the N-benzyl-protected
substrate 5q was treated under the standard enolate
arylation conditions, the reaction afforded only the ben-
zodiazepinone 7b in an unoptimized 60% yield. This
suggests that the balance between enolate and direct indole
arylation can be engineered by modification of the
substrate structure as well as the reaction conditions.
a Isolated yield. b 1:1 mixture of diastereoisomers.
A further interesting class of substrates we wished to
examine was the N-indolyl-substituted substrates 5p,q.
These are of interest since the transformation could serve
as an approach to the 3-(N-indolyl)-substituted indole
alkaloids such as the kapakahines,17 the chetomin/cheto-
seminudin/chaetococcin family,18 and psychotrimine (4),4
(18) (a) McInnes, A. G.; Taylor, A.; Walter, J. A. J. Am. Chem. Soc.
1976, 98, 6741. (b) Fujimoto, H.; Sumino, M.; Okuyama, E.; Ishibashi, M.
J. Nat. Prod. 2004, 67, 98. (c) Li, G.-Y.; Li, B.-G.; Yang, T.; Yan, J.-F.;
Liu, G.-Y.; Zhang, G.-L. J. Nat. Prod. 2006, 69, 1374.
(19) Matsuda, Y.; Kitajima, M.; Takyama, H. Org. Lett. 2008, 10, 125.
(20) (a) Batt, D. G.; Qiao, J. X.; Modi, D. P.; Houghton, G. C.; Pierson,
D. A.; Rossi, K. A.; Luettgen, J. M.; Knabb, R. M.; Jadhav, P. K.; Wexler,
R. R. Bioorg. Med. Chem. Lett. 2004, 14, 5269. (b) Bennasar, M.-L.; Zulaica,
E.; Alonso, Y.; Vidal, B.; Vazquez, J. T.; Bosch, J. Tetrahedron: Asymmetry
2002, 13, 95, and references therein. (c) Della Salla, G.; Capozzo, D.; Izzo,
I.; Giordano, A.; Iommazzo, A.; Spinella, A. Tetrahedron Lett. 2002, 43,
8839. (d) Christie, B. D.; Rapoport, H. J. Org. Chem. 1985, 50, 1239.
(21) Other examples of palladium-catalyzed C2-arylation of N-alkylin-
doles:(a) Kozikowski, A. P.; Ma, D. Tetrahedron Lett. 1991, 32, 3317. (b)
Kozikowski, A. P.; Ma, D.; Brewer, J.; Sun, S.; Costa, E.; Romeo, E.;
Guidotti, A. J. Med. Chem. 1993, 36, 2908. (c) Desarbre, E.; Me´rour, J.-Y.
Heterocycles 1995, 41, 1987. (d) Toure´, B. B.; Lane, B. S.; Sames, D. Org.
Lett. 2006, 8, 1979. (e) Avila-Zarraga, J. G.; Lujan-Montelongo, A.;
Covarrubias-Zuniga, A.; Romero-Ortega, M. Tetrahedron Lett. 2006, 47,
7987. (f) Beccalli, E. M.; Broggini, G.; Martinelli, M.; Paladino, G.; Rossi,
E. Synthesis 2006, 2404.
(15) (a) Freund, R.; Mederski, W. W. K. R. HelV. Chim. Acta 2000, 83,
1247. (b) Zhang, T. Y.; Zhang, H. Tetrahedron Lett. 2002, 43, 193. (c)
Zhang, T. Y.; Zhang, H. Tetrahedron Lett. 2002, 43, 1363. (d) Bignan,
G. C.; Battista, K.; Connolly, P. J.; Orsini, M. J.; Liu, J.; Middleton, S. A.;
Reitz, A. B. Bioorg. Med. Chem. Lett. 2005, 15, 5022.
(16) (a) Glorius, F.; Altenhoff, G.; Goddard, R.; Lehmann, C. Chem.
Commun. 2002, 2704. (b) Arao, T.; Kondo, K.; Aoyama, T. Chem. Pharm.
Bull. 2006, 54, 1743. (c) Arao, T.; Kondo, K.; Aoyama, T. Tetrahedron
Lett. 2006, 47, 1417. (d) Ku¨ndig, E. P.; Seidel, T. M.; Jia, Y.-X. Angew.
Chem., Int. Ed. 2007, 46, 8484.
(17) (a) Nakao, Y.; Yeung, B. K. S.; Yoshida, W. Y.; Scheuer, P. J.;
Kelly-Borges, M. J. Am. Chem. Soc. 1995, 117, 8271. (b) Yeung, B. K. S.;
Nakao, Y.; Kinnel, R. B.; Carney, J. R.; Yoshida, W. Y.; Scheuer, P. J.;
Kelly-Borges, M. J. Org. Chem. 1996, 61, 7168. (c) Nakao, Y.; Kuo, J.;
Yoshida, W. Y.; Kelly, M.; Scheuer, P. J. Org. Lett. 2003, 5, 1387.
Org. Lett., Vol. 10, No. 13, 2008
2907